<DOC>
	<DOCNO>NCT01153386</DOCNO>
	<brief_summary>This study compare bioavailability pharmacokinetics 0.5 mg , 1 mg 2.5 mg treprostinil diethanolamine tablet strength healthy volunteer .</brief_summary>
	<brief_title>Pharmacokinetic Linearity Comparative Bioavailability Treprostinil Diethanolamine</brief_title>
	<detailed_description>This study design assess pharmacokinetic linearity comparative bioavailability UT-15C SR ( treprostinil diethanolamine ) follow administration single tablet contain 0.5 mg , 1 mg 2.5 mg UT-15C healthy volunteer .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Subject healthy age 18 55 year Female subject must weigh 55 100 kg , inclusive , BMI 19.029.9 kg/m2 , inclusive Screening . Male subject must weigh 55 120 kg , inclusive , BMI 19.032.0 kg/m2 , inclusive Screening . Subject medical history , physical examination , vital sign , ECG clinical laboratory result within normal limit consider clinically significant Investigator Screening . Subject clinically relevant abnormality identify screen physical examination , 12lead ECG , laboratory examination . Subject history anaphylaxis , document hypersensitivity reaction , clinically significant idiosyncratic reaction drug . Subject clinically significant history neurological , cardiovascular , respiratory , endocrine , hematological , hepatic , renal , gastrointestinal , genitourinary , pulmonary and/or musculoskeletal disease ; glaucoma ; psychiatric disorder chronic disease , whether control medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>Treprostinil</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>